INCYTE CORPORATION

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. You have been given clear instructions, reach out to us before it's too late.

Incyte Corporation reported a data breach to the Indiana Attorney General. The breach occurred on 2024-02-21 and was reported on 2024-05-23. 595 Indiana residents were affected.

Cencora, Inc. notified the California Attorney General of a data breach discovered on February 21, 2024, involving the exfiltration of data from its information systems. Affected data may include names, addresses, dates of birth, health diagnoses, and medications. Cencora engaged law enforcement and cybersecurity experts, contained the incident, and is offering 24 months of credit monitoring to affected individuals.

Incyte Corporation's 10-K Item 1C cybersecurity disclosure describes their cybersecurity program governance and risk management practices. The company states it has not experienced a cybersecurity incident that has resulted in a material adverse impact to its business or operations to date. No specific incident is reported.